PB
Pivotal bioVenture Partners
Pivotal bioVenture Partners is a Series A to Series D stage investment firm. It has made 10 investments. Average disclosed round size is $91.5M (across 13 rounds with reported amounts).
Portfolio
10
Fund Size
—
Top Stage
Series C
Last 12 Mo
1
Team
DL
Dan Liu
Managing Partner
RH
Rob Hopfner
Managing Partner
PB
PETER BIsGaARD
MANAGING director
VC
Vincent Cheung
Managing Director
YW
Yutong W.
Investment Associate
JL
Jeni Lee
Life sciences investor
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
13 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| CCrystalys Therapeutics Inc | Series B | $130M | Jul 2026 |
 Avalyn Pharma, Inc. | Series D | $100M | Jul 2025 |
| MMosanna | Series A | $80M | Jan 2025 |
| EEVOMMUNE INC. | Series C | $115M | Oct 2024 |
| VVigil Neurosciences | Unknown | $90M | Aug 2021 |
| BBolt Biotherapeutics, Inc. | Series C | $93.5M | Jul 2020 |
 Aligos | Series B | $125M | Jan 2020 |
| EEVOMMUNE INC. | Seed | $12.5M | Jan 2020 |
| KKaruna Therapeutics | Unknown | $68M | Jan 2019 |
| KKaruna Therapeutics | Series A | $42M | Jan 2018 |
| SSutroVax | Series D | $110M | Mar 2017 |
| Avalyn Pharma, Inc. | Series C | $175M | — |
| IInozyme Pharma | Series A | $49M | — |
Top Co-Investors
Rock Springs Capital5 shared
Novo Holdings4 shared
Wellington Management4 shared
Eventide Asset Management4 shared
Surveyor Capital4 shared
RA Capital Management4 shared
Cormorant Asset Management3 shared
Alexandria Venture Investments3 shared
SR One3 shared
Norwest Venture Partners3 shared
Sofinnova Partners3 shared
Longwood Fund2 shared
Lightstone Ventures2 shared
Catalio Capital Management2 shared
F-Prime Capital2 shared
RiverVest Venture Partners2 shared
T. Rowe Price2 shared
Novo Holdings A/S2 shared
Longitude Capital2 shared
Last updated: 8 September 2026